For the Media
Dr. Nicole Frahm is an associate member of Fred Hutchinson Cancer Research Center's Vaccine and Infectious Disease Division. She oversees the HIV Vaccine Trial Network’s laboratory program at Fred Hutch in Seattle. The lab focuses on the cellular immune response to HIV infection. A major focus of the lab program is to identify correlates of protection (CoP), which are immune markers that indicate protection from infection. RV144, the first HIV vaccine trial to show protection, allowed the ability to propose CoPs.
At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first National Cancer Institute-funded cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network.